1201903-02-7

Basic information

• Product Name: Ixazomib Impurity 1
• Synonyms: Ixazomib Impurity 1;2,5-dichloro-N-(2-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-2-oxoethyl)benzamide
• CAS NO: 1201903-02-7
• Molecular Formula: C₂₄H₃₃BCl₂N₂O₄
• Molecular Weight: 495.24682
• Mol File: 1201903-02-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Dichloromethane; Chloroform; Methanol; Ethyl Acetate; DMSO
• CAS DataBase Reference: Ixazomib Impurity 1(CAS DataBase Reference)
• NIST Chemistry Reference: Ixazomib Impurity 1(1201903-02-7)
• EPA Substance Registry System: Ixazomib Impurity 1(1201903-02-7)

Safety Data

• Hazardous Substances Data: 1201903-02-7(Hazardous Substances Data)

Usage

Description

Ixazomib Impurity 1, also known as 2,5-Dichloro-N-[2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxoethyl]-benzamide, is an intermediate compound used in the synthesis of Ixazomib (I942000). Ixazomib is a proteasome inhibitor that prevents cell growth in solid tumors, making it an effective anticancer agent. It is primarily used to treat patients with multiple myeloma and has potential neurotoxic effects.

Uses

Used in Pharmaceutical Industry:
Ixazomib Impurity 1 is used as an intermediate in the synthesis of Ixazomib, an anticancer agent, for its role in preventing cell growth in solid tumors.
Ixazomib Impurity 1 is used as a component in the development of proteasome inhibitors for the treatment of multiple myeloma patients, due to its contribution to the overall synthesis process of Ixazomib.
Additionally, Ixazomib Impurity 1 plays a role in the study and understanding of the potential neurotoxic effects of Ixazomib, as it is an integral part of the synthesis pathway.

Upstream product

• 18680-27-8 pinanediol 
• 667403-46-5 2-[(2,5-dichlorobenzoyl)amino]acetic acid 
• 779357-85-6 (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxabor-ol-2-yl]butan-1-amine hydrochloride 
• 85167-14-2 (3aS,4S,6S,7aR)-2-[(1S)-1-chloro-3-methylbutyl]-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole 
• 84110-34-9 2-(2-methylpropyl)-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole 
• 1310383-72-2 (aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate 
• 50-79-3 2,5-dichlorobenzoic acid 
• 179324-86-8 (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^2,6]decan-4-yl]butan-1-amine 
• 2905-61-5 2,5-dichlorobenzoyl chloride 

Downstream Products

• 1201903-03-8 Ν,Ν',Ν''-[boroxin-2,4,6-triyltris[[(1R)-3-methylbutane-1,1-diyl]imino(2-oxoethane-2,1-diyl)]]tris(2,5-dichlorobenzamide) 
• 1239908-20-3 2,2’-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid 
• 1072833-77-2 Ixazomib 

Relevant articles and documents

Virtues of Volatility: A Facile Transesterification Approach to Boronic Acids

Boronic acids are an increasingly important compound class for many applications, including C-C bond formation reactions, medicinal chemistry, and diagnostics. The deprotection of boronic ester intermediates is frequently a problematic and inefficient step in boronic acid syntheses. We describe an approach that highly facilitates this transformation by leveraging the volatility of methylboronic acid and its diol esters. The method is performed under mild conditions, provides high yields, and eliminates cumbersome and problematic purification steps.

NOVEL CRYSTALLINE FORMS OF IXAZOMIB CITRATE AND ITS PROCESS FOR PREPARATION THEREOF

The present invention related to novel crystalline forms of Ixazomib citrate of formula-I and its process for preparation thereof. The chemical structure of said compound represented by the following formula-I. This invention also provides a process for the preparation of Ixazomib citrate of formula-I and also its solid dispersions.

Deuterated dipeptide boric acids or esters thereof, and synthetic methods and uses of the compounds

Deuterated dipeptide boric acids or esters thereof, or crystal forms thereof, or pharmaceutically acceptable hydrates or solvates thereof are disclosed. The general structure of the compounds is shown as a formula (a) in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, deuterium or halogens, or C1-C4 alkyl one or a plurality of or all hydrogen atoms of which are deuterated; and at least one of the R1, the R2, the R3, the R4, the R5 and the R6 is deuterated or deuterium. The compounds can effectively inhibit proteasomes and effectively treat or prevent cancer, cardiovascular disease, inflammation, immune disease, nephropathy, vasculogenesis or prostate disease.